SCHEMBL1979795

SCHEMBL1979795

NC1(O)c2ccccc2Oc2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 2/20 0.41
ALOX5 P09917 2/20 0.41
MAOA P21397 2/20 0.38
MAOB P27338 2/20 0.38
ATM Q13315 1/20 0.36
AHR P35869 2/20 0.35
CYP2C9 P11712 2/20 0.35
MEN1 O00255 2/20 0.35
CYP2C19 P33261 2/20 0.35
KMT2A Q03164 2/20 0.35
GAA P10253 1/20 0.35
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
P2RX4 Q99571 1/20 0.32
PDK2 Q15119 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
HTT P42858 1/20 0.32
RECQL P46063 1/20 0.32
BLM P54132 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21842178 0.80 ALOX5 (0.44) CHRM3ALOX5MAOAMAOBATM
SCHEMBL7970207 0.80 ALOX5 (0.44) CHRM3ALOX5MAOAMAOBATM
SCHEMBL1461770 0.80 ALOX5 (0.44) CHRM3ALOX5MAOAMAOBATM
SCHEMBL28586543 0.76 ALOX5 (0.41) CHRM3ALOX5MAOAMAOBATM
SCHEMBL13672457 0.76 CHRM3 (0.45) CHRM3ALOX5MAOAMAOBAHR
SCHEMBL6129309 0.76 CHRM3 (0.41) CHRM3ALOX5MAOAMAOBATM
SCHEMBL18535897 0.76 CHRM3 (0.41) CHRM3ALOX5MAOAMAOBATM
SCHEMBL3289558 0.74 ALOX5 (0.48) CHRM3ALOX5MAOAMAOBATM
SCHEMBL896505 0.73 PNMT (0.39) CHRM3ALOX5MAOAMAOBAHR
SCHEMBL29722 0.73 CHRM3 (0.46) CHRM3ALOX5MAOAMAOBAHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160354533-A1 ADSORBING PATHOGEN-INACTIVATING COMPOUNDS WITH POROUS PARTICLES IMMOBILIZED IN A MATRIX CERUS CORPORATION (US) 2016-12-08 US disclosed
US-9259525-B2 Adsorbing pathogen-inactivating compounds with porous particles immobilized in a matrix CERUS CORPORATION (US) 2016-02-16 US disclosed
EP-2358814-B1 PLASTICIZER FOR THERMOPLASTIC POLYMER MATERIALS AVENT INC (US) 2015-07-29 EP disclosed
EP-1508345-B1 System and method for the reduction of small organic compounds from blood products CERUS CORP (US) 2013-09-25 EP disclosed
US-8518315-B2 Plasticizer for thermoplastic materials KIMBERLY-CLARK WORLDWIDE, INC. (US) 2013-08-27 US disclosed
EP-2358814-A2 PLASTICIZER FOR THERMOPLASTIC POLYMER MATERIALS Kimberly-Clark Worldwide, Inc. (US) 2011-08-24 EP disclosed
US-20110143621-A1 PLASTICIZER FOR THERMOPLASTIC POLYMER MATERIALS AVANOS MEDICAL SALES, LLC 2011-06-16 US disclosed
US-7759302-B2 Octapeptides: Arg-X-Asp-Leu-Asp-Ser-Leu-Arg where X is a 2-aminoaulfonylaminoalkanoic acid and optionally having various end groups; biologically active as ligands of blood platelet integrin GPIIbIIIa and the alpha v integrins MERCK PATENT GMBH (DE) 2010-07-20 US disclosed
US-20100160484-A1 XANTHENE-BASED PLASTICIZER OF RESINS AND POLYMERS AVANOS MEDICAL SALES, LLC 2010-06-24 US disclosed
US-20100159769-A1 PLASTICIZER FOR THERMOPLASTIC MATERIALS AVANOS MEDICAL SALES, LLC 2010-06-24 US disclosed
EP-1044066-A1 BATCH DEVICES FOR THE REDUCTION OF COMPOUNDS FROM BIOLOGICAL COMPOSITIONS CONTAINING CELLS AND METHODS OF USE Cerus Corporation (US) 2000-10-18 EP disclosed
CN-1248178-A Method and device for reducing small organic molecules in blood products CERUS CORP (US) 2000-03-22 CN disclosed
EP-0954374-A1 METHODS AND DEVICES FOR THE REDUCTION OF SMALL ORGANIC COMPOUNDS FROM BLOOD PRODUCTS Cerus Corporation (US) 1999-11-10 EP disclosed
WO-1999034914-A1 BATCH DEVICES FOR THE REDUCTION OF COMPOUNDS FROM BIOLOGICAL COMPOSITIONS CONTAINING CELLS AND METHODS OF USE CERUS CORPORATION (US) 1999-07-15 WO disclosed
WO-1999034915-A1 FLOW DEVICES FOR THE REDUCTION OF COMPOUNDS FROM BIOLOGICAL COMPOSITIONS AND METHODS OF USE CERUS CORPORATION (US) 1999-07-15 WO disclosed
WO-1998030327-A1 METHODS AND DEVICES FOR THE REDUCTION OF SMALL ORGANIC COMPOUNDS FROM BLOOD PRODUCTS CERUS CORPORATION (US) 1998-07-16 WO disclosed
EP-0471794-B1 ANTIVIRAL THERAPY USING THIAZINE AND XANTHENE DYES OKLAHOMA MED RES FOUND (US) 1996-10-02 EP disclosed
EP-0471794-A4 ANTIVIRAL THERAPY USING THIAZINE AND XANTHENE DYES 1992-05-06 EP disclosed
EP-0471794-A1 ANTIVIRAL THERAPY USING THIAZINE AND XANTHENE DYES. OKLAHOMA MED RES FOUND (US) 1992-02-26 EP disclosed
WO-1990013296-A1 ANTIVIRAL THERAPY USING THIAZINE AND XANTHENE DYES OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) 1990-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160484-A1 XANTHENE-BASED PLASTICIZER OF RESINS AND POLYMERS SMARCA2, SMARCA1, MYB CHRM3 724/4885ALOX5 805/4885MAOA 1730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.